跳至主要内容
临床试验/NCT02611583
NCT02611583撤回不适用

Double-blind, Randomized, Placebo Controlled Trial of Transcutaneous Electrical Nerve Stimulation (TENS) Treatment Plus Ibuprofen for the Treatment of Acute Back Pain in the Emergency Department

Albert Einstein Healthcare Network2 个研究点 分布在 1 个国家开始时间: 2016年6月24日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Change in visual analog scale (VAS)

研究概览

简要总结

Patients presenting to the ED with a chief complaint of acute low back pain and whom the providing physician feels symptomatic treatment is appropriate in the ED will be screened for inclusion in the study. The purpose of the study is to compare Transcutaneous Electrical Nerve Stimulation (TENS) as an adjunct to ibuprofen in the treatment of acute low back pain in the emergency department. Therefore, the aim of this prospective, randomized, double blind study is to evaluate the efficacy of ED administered TENS in acute low back pain patients during their ED visit.

详细描述

The study is a double blind, randomized, placebo controlled trial. One group will receive ibuprofen and TENS. The comparison group will receive ibuprofen and sham TENS. The study primary endpoint is change in pain level on Visual Analog Scale score at 45-60 minutes after TENS start.

This is a two-arm, double blind, randomized control trial evaluating the patient perceived improvement in back pain. Patients will first fill out a Visual Analog Scale (VAS).

Patients will be randomized to one of two arms. Ibuprofen 800 mg, plus sham TENS for 45 minutes Ibuprofen 800 mg, plus TENS for 45 minutes

Patients will be given a 2nd VAS scale up to 15 minutes after the end of the TENS session. After the second VAS the patients will be finished with the study procedures and can be continued to be cared as per the discretion of their treating physician.

Our intention is to detect a 20% reduction in pain by VAS with a common standard deviation equal to the difference at the p = 0.05 level with a power of 80% using an analysis of variance (ANOVA). The calculated sample size required 28 patients per group. Considering the uncertain dropout rate, the investigators decided to enroll at least 66 patients. Baseline characteristics will be calculated to determine if groups are equal. A two-way repeated-measures ANOVA will be used to test both a trial effect and a group effect (SPSS 20, SPSS Inc., Chicago, IL). Data will be presented as means with standard deviations with 95% confidence intervals. A p< 0.05 was considered statistically significant.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients 18 years to 65 years of age presenting to the emergency room with a primary complaint of low back pain.
  • Patient is receiving 800mg dose of ibuprofen as part of their treatment regimen for back pain
  • Back pain new in the last 48 hours
  • Deemed by the treating physician to have musculoskeletal back pain, and no central/peripheral nervous system pathology as the cause of their pain.

排除标准

  • Allergy to ibuprofen.
  • Hypotension (MAP <65 or Systolic BP <100), fever, tachycardia
  • Paresthesias, isolated motor weakness, or objective sensory deficit on physical exam
  • Radicular symptoms
  • Urinary incontinence or retention
  • Bowel incontinence
  • Unexplained weight loss of >15 lbs in the last 3 months.
  • Multiple primary complaints in the ED.
  • Received Analgesia other than Ibuprofen as part of their ED work up.
  • Taken prescription strength pain medication within the last 12 hours for any condition.
  • History of active malignancy, HIV, organ transplantation, active hemodialysis
  • Currently pregnant
  • Nursing home residents
  • Currently in police custody

结局指标

主要结局

Change in visual analog scale (VAS)

时间窗: 0 minutes, 45 minutes

Patients will have a baseline and 45 minutes VAS performed

次要结局

  • Treatment failure(45 minutes)
  • Adverse events(60 minutes)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Paul Dominici

MD

Albert Einstein Healthcare Network

研究点 (2)

Loading locations...

相似试验